Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation

Shuai Wang, Lei Han, Jungsoo Han, Peng Li, Qing Ding, Qing Jun Zhang, Zhi Ping Liu, Chuo Chen, Yonghao Yu

Research output: Contribution to journalArticlepeer-review

46 Scopus citations


PARP1 inhibitors (PARPi) are known to kill tumor cells via two mechanisms (PARP1 catalytic inhibition and PARP1 trapping). The relative contribution of these two pathways in mediating the cytotoxicity of PARPi, however, is not well understood. Here we designed a series of small molecule PARP degraders. Treatment with one such compound iRucaparib-AP6 results in highly efficient and specific PARP1 degradation. iRucaparib-AP6 blocks the enzymatic activity of PARP1 in vitro, and PARP1-mediated poly-ADP-ribosylation signaling in intact cells. This strategy mimics PARP1 genetic depletion, which enables the pharmacological decoupling of PARP1 inhibition from PARP1 trapping. Finally, by depleting PARP1, iRucaparib-AP6 protects muscle cells and primary cardiomyocytes from DNA-damage-induced energy crisis and cell death. In summary, these compounds represent ‘non-trapping’ PARP1 degraders that block both the catalytic activity and scaffolding effects of PARP1, providing an ideal approach for the amelioration of the various pathological conditions caused by PARP1 hyperactivation.

Original languageEnglish (US)
Pages (from-to)1223-1231
Number of pages9
JournalNature chemical biology
Issue number12
StatePublished - Dec 1 2019

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation'. Together they form a unique fingerprint.

Cite this